Oncology

Articles:
232 Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1903835

231 Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses.
https://stm.sciencemag.org/content/11/498/eaat8549

230 Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)30723-8/fulltext

229 Ibrutinib and Venetoclax for First-Line Treatment of CLL.
https://www.nejm.org/doi/full/10.1056/NEJMoa1900574

228 Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1817249

227 Reprogramming the microenvironment with tumor-selective angiotensin blockers enhances cancer immunotherapy.
https://www.pnas.org/content/116/22/10674

226 Methionine is a metabolic dependency of tumor-initiating cells.
https://www.nature.com/articles/s41591-019-0423-5

225 Preventable Cancer Burden Associated with Poor Diet in the United States.
https://academic.oup.com/jncics/advance-article/doi/10.1093/jncics/pkz034/5492023?searchresult=1

224 PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.
https://www.pnas.org/content/116/20/9999

223 Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1816714?query=featured_home

222 Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1814017?query=featured_home

221 Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
https://www.pnas.org/content/116/6/2210

220 First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1809064

219 Mannose impairs tumour growth and enhances chemotherapy.
https://www.nature.com/articles/s41586-018-0729-3

218 Human-like hyperplastic prostate with low ZIP1 induced solely by Zn deficiency in rats.
http://www.pnas.org/content/115/47/E11091

217 CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1807315

216 Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1805762?query=featured_home

215 Enhanced detection of circulating tumor DNA by fragment size analysis.
http://stm.sciencemag.org/content/10/466/eaat4921

214 Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1809615

213 Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
https://www.nejm.org/doi/full/10.1056/NEJMoa1802905

212 Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
https://www.nejm.org/doi/full/10.1056/NEJMoa1805453

211 Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1805104

210 Prediction of acute myeloid leukaemia risk in healthy individuals.
https://www.nature.com/articles/s41586-018-0317-6

209 Cancer prevalence among flight attendants compared to the general population.
https://ehjournal.biomedcentral.com/articles/10.1186/s12940-018-0396-8

208 Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1804710?query=featured_home

207 Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1801005

206 Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
https://www.nejm.org/doi/full/10.1056/NEJMoa1801946

205 Higher Lung Cancer Incidence in Young Women Than Young Men in the United States.
https://www.nejm.org/doi/full/10.1056/NEJMoa1715907

204 Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
https://www.nejm.org/doi/full/10.1056/NEJMoa1716078

203 Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis.
http://stm.sciencemag.org/content/10/441/eaap8307

202 Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
https://www.nejm.org/doi/full/10.1056/NEJMoa1802357

201 Analyses of genomes from 914 children, adolescents, and young adults provide a comprehensive resource of genomic alterations across a spectrum of common childhood cancers.
https://www.nature.com/articles/nature25480

200 Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1714678

199 Detection and localization of surgically resectable cancers with a multi-analyte blood test.
http://science.sciencemag.org/content/early/2018/01/17/science.aar3247

198 Contemporary Hormonal Contraception and the Risk of Breast Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1700732

197 Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
http://www.pnas.org/content/114/48/E10369.abstract

196 Lomustine and Bevacizumab in Progressive Glioblastoma.
http://www.nejm.org/doi/full/10.1056/NEJMoa1707358

195 Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.
http://www.nejm.org/doi/full/10.1056/NEJMoa1709937

194 Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31601-X/fulltext

193 Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32247-X/fulltext

Free Images for Presentation: sunipix SUNIPIX